Vimentin, Recombinant, Human (FLJ36605, VIM)

Vimentin expression in human malignant glioma cells depends on cellular density, algorithms of drug delivery and chemo/radio treatment. Vimentin and detyrosinated microtubules provide structural support for the extensive microtentacles observed in detached tumor cells and a mechanism to promote successful metastic spread. Primary colorectal carcinomas display aberrant expression of Vimentin, and have activated Notch and TGF-beta signaling pathways. Vimentin is a strong arterial substrate for transglutaminases. Transglutaminase-mediated Vimentin dimerization results in a novel unifying pathway by which vasodilatory and remodeling responses may be regulated. Ablation of Vimentin expression inhibits migraion and invasion of colon and breast cancer cell lines. Vimentin is the main intermediate filament protein in mesenchymal cells and is therefore of value in the differential diagnosis of undifferentiated neoplasms.\n\nRecombinant Human Vimentin produced in E. coli is a non-glycosylated, polypeptide chain. On SDS-PAGE commassie blue stained gel, the purified recombinant protein shows a band at 57kD.\n\nReconstitution to Filaments:\nAfter Vimentin is dissolved, protofilaments and filament complexes are obtained by dialyzing the resulting polypeptide solution stepwise to a concentration of 4M urea and then to low salt condition (50mM sodium chloride, 2mM dithiothreitol, 10mM Tris-HCl, pH 7.4). For immunization purposes, the solution can be further dialyzed against PBS (phosphate buffered saline, e.g. Dulbecco

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2122-15

Size

2ug

Applications

ELISA, WB

Reactivities

Hum

Form

Supplied as a lyophilized powder in 30mM Tris-HCl, pH 8.0, 9.5M urea, 2mM EDTA, 2mM DTT, 10mM methylammonium chloride. Reconstitute with sterile ddH2O., 0.1% HSA or BSA to (same/more than) 0.1mg/ml. This solution can then be diluted into other aqueous solutions.

Purity

~ 95%; Determined by SDS-gel electrophoresis.

References

1. J. Neuroendocrinol. 17(3): 135-144 (2005). 2. Exp. Cell Res. 305(1): 110-121 (2005). 3. Vet. Pathol. 42(2): 161-165 (2005). 4. Neuron 45(5): 715-726 (2005). 5. J. Biol. Chem. 280(17): 16,882-16,890 (2005). 6. J. Neurotrauma 21(11): 1671-1682 (2004). 7. Hatzfeld, M., et al., J. Mol. Biol. 197: 237-255 (1987). 8. Hatzfeld, M. and Franke, W.W., J. Cell Biol. 101: 1826-1841 (1985).